Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-κB as a target

• Published in: Journal of cellular biochemistry Vol. 92; no. 4; pp. 646 - 650
• Main Authors: Monks, N.R., Biswas, D.K., Pardee, A.B.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01-07-2004
• Subjects: apoptosis; Go6976; inhibitors; NF-κB; siRNA
• ISSN: 0730-2312; 1097-4644
• DOI: 10.1002/jcb.20080

Critical processes underlying cancers must be better understood to develop strategies for treatment and prevention. A chemotherapeutic strategy is proposed that is based upon re‐establishment, with a drug, of nullified programmed cell death (apoptosis) in cancer cells, which to survive have mutated to block apoptosis. A chemotherapy that is specific against tumors implanted in mice demonstrated the feasibility of this principle. This therapy is specific because it affects a process unique to cancer cells. It also has the advantage of killing these cells, in contrast to reversibly blocking their proliferation. The anti‐apoptotic transcription factor NF‐κB provides a potential therapeutic target in estrogen receptor negative (ER−) breast cancers that over‐express the epidermal growth factor family of receptors (EGFR). Further investigations of the pathways utilize dominant negative protein inhibitory peptide, and small inhibitory RNAs (siRNAs) to block the production of relevant enzymes. © 2004 Wiley‐Liss, Inc.